Jianfeng Group: Estimated net loss of 7 million to 10 million yuan in the first half of 2026

On July 14, Jianfeng Group issued a performance pre-loss announcement, the company expects to achieve a net profit of-10 million yuan to-7 million yuan attributable to shareholders of listed companies in the first half of 2026, compared with the same period last year, there will be a loss. In the first half

of 2026, due to the continuous adjustment of the real estate industry, the slowdown of infrastructure projects and other factors, the national cement demand further declined. According to the data of the National Bureau of Statistics, from January to May 2026, the total cement output of cement enterprises above the national scale reached 591 million tons, down 8.6% from the same period last year.

During the reporting period, the sales price of the company's cement products decreased year on year, the revenue decreased, and the gross profit margin decreased. Due to factors such as medical insurance fee control and centralized procurement policy, the sales prices of preparations, APIs and intermediates in the pharmaceutical sector of the company have further declined, the revenue of pharmaceutical business has declined, and the gross profit margin has decreased. In addition, in the same period of last year, Tasly Bio-Pharmaceutical Industry Group Co., Ltd., a joint venture accounted for by the equity method of the Company, obtained a relatively large non-recurring income due to the sale of the equity of Tasly Pharmaceutical Group Co., Ltd., while Tasly Group did not have such income in the current period.